BioNTech (BNTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$3.70
- EPS estimate
- −$3.70
- EPS surprise
- +0.00%
- Revenue surprise
- −28.82%
- Revenue
- $120.6M
- Revenue estimate
- $169.4M
- Reported
- Aug 4, 2026
BioNTech reported Q2 2026 results on August 4, 2026, posting a loss of $3.70 per share, in line with the estimate. Revenue was $120.6 million, 28.82% below the $169.4 million estimate. Compared with Q2 2025, the loss widened from $1.88 per share, and revenue fell about 61% from $307.2 million. Both the loss and the revenue figure are the weakest in the table.
In 2022, BioNTech earned $39.27 per share, with quarterly revenue between $3.4 billion and $7.1 billion. Annual EPS then fell to $4.17 in 2023, before losses of $2.99 per share in 2024 and $5.36 in 2025. The first half of 2026 shows a combined loss of $6.13, against $3.75 a year earlier. Revenue has been uneven within each year: Q3 2025 brought $1.8 billion, while the last four first-half quarters ranged from $120.6 million to $307.2 million. Over the last 20 quarters, EPS beat estimates 14 times.
Q3 results came between November 3 and November 9 in each of the past five years, which points to early November 2026 for the next report. It will show whether revenue again rises in the second half and how the result compares with the $0.14 loss of Q3 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | −$3.70 | −$3.70 | +0.00% | $120.6M | SEC |
| Q1 2026 | May 5, 2026 | −$2.54 | −$2.43 | +4.42% | $136.4M | SEC |
| Q4 2025 | Mar 10, 2026 | −$0.19 | −$1.47 | −673.50% | $1.1B | SEC |
| Q3 2025 | Nov 3, 2025 | −$1.12 | −$0.14 | +87.40% | $1.8B | SEC |
| Q2 2025 | Aug 4, 2025 | −$2.69 | −$1.88 | +29.91% | $307.2M | SEC |
| Q1 2025 | May 5, 2025 | −$2.48 | −$1.87 | +24.47% | $197.8M | SEC |
| Q4 2024 | Mar 10, 2025 | $0.46 | $1.12 | +141.78% | $1.2B | SEC |
| Q3 2024 | Nov 4, 2024 | −$1.74 | $0.90 | +151.79% | $1.4B | SEC |
| Q2 2024 | Aug 5, 2024 | −$2.19 | −$3.60 | −64.22% | $137.9M | SEC |
| Q1 2024 | May 6, 2024 | −$1.34 | −$1.41 | −5.37% | $202.4M | SEC |
| Q4 2023 | Mar 20, 2024 | $2.62 | $2.10 | −20.00% | $1.6B | SEC |
| Q3 2023 | Nov 6, 2023 | −$0.62 | $0.71 | +213.55% | $946.4M | SEC |
| Q2 2023 | Aug 7, 2023 | −$0.91 | −$0.86 | +5.21% | $182.9M | SEC |
| Q1 2023 | May 8, 2023 | $0.29 | $2.22 | +673.34% | $1.4B | SEC |
| Q4 2022 | Mar 27, 2023 | $8.32 | $9.91 | +19.05% | $4.6B | SEC |
| Q3 2022 | Nov 7, 2022 | $3.35 | $6.84 | +104.07% | $3.4B | — |
| Q2 2022 | Aug 8, 2022 | $7.42 | $6.76 | −8.93% | $3.4B | — |
| Q1 2022 | May 9, 2022 | $10.14 | $15.76 | +55.42% | $7.1B | — |
| Q4 2021 | Mar 30, 2022 | $8.46 | $13.84 | +63.65% | $6.3B | — |
| Q3 2021 | Nov 9, 2021 | $12.20 | $14.30 | +17.18% | $7.0B | — |
Quarterly revenue
Frequently asked questions
When did BioNTech (BNTX) last report earnings?
BioNTech last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did BNTX beat earnings estimates?
BioNTech reported EPS of −$3.70 for Q2 2026, in line with the −$3.70 consensus estimate.
How much revenue did BNTX report last quarter?
BioNTech reported $120.6M in revenue for Q2 2026, against a consensus estimate of $169.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.